



J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Phone: 022-2482 2222/ 2493 0918 Fax : 022 – 2493 0534/ 2493 9633
 CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31/12/2015

Sl.No.	Particulars	Quarter ended			Nine Months ended		Previous Year ended
		31-12-2015	30-09-2015	31-12-2014	31-12-2015	31-12-2014	31-03-2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	a. Net sales (Net of excise duty)	27,058.46	28,070.95	25,680.59	83,044.34	78,837.90	1,03,813.61
	b. Other Operating Income	776.95	607.15	666.25	1,890.02	1,794.99	2,328.51
	Total Income from Operations (Net) (a+b)	27,835.41	28,678.10	26,346.84	84,934.36	80,632.89	1,06,142.12
2	Expenses						
	a. Cost of materials consumed	9,497.53	9,819.75	8,411.04	28,340.26	25,453.51	34,158.73
	b. Purchases of stock-in-trade	1,073.13	2,003.69	1,629.84	5,385.92	7,102.75	9,009.66
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(395.41)	(189.50)	278.90	14.63	208.96	(68.24)
	d. Employee benefits expense	3,910.55	4,033.19	3,551.38	12,040.75	10,822.88	14,681.81
	e. Depreciation and amortization expense	1,022.56	1,004.00	1,011.00	3,003.56	3,002.00	3,759.99
	f. Exchange Fluctuation Transactional (Gain)/Loss	66.70	86.78	41.70	272.20	18.22	58.16
	g. Other Expenses	7,222.56	7,556.39	7,578.87	22,099.58	21,579.68	28,633.60
	Total Expenses	22,397.62	24,314.30	22,502.73	71,156.90	68,188.00	90,233.71
3	Profit from Operations before Other Income and Finance Cost (1-2)	5,437.79	4,363.80	3,844.11	13,777.46	12,444.89	15,908.41
4	Other Income	1,290.99	2,651.63	195.92	4,372.33	890.40	1,040.88
5	Profit from ordinary activities before Finance Cost (3+4)	6,728.78	7,015.43	4,040.03	18,149.79	13,335.29	16,949.29
6	Finance Cost	259.83	308.41	284.71	739.27	642.68	665.01
7	Profit from ordinary activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	6,468.95	6,707.02	3,755.32	17,410.52	12,692.61	16,284.28
8	Exchange Fluctuation Translation Gain / (Loss)	35.27	(478.49)	(241.28)	(44.58)	(654.80)	(373.86)
9	Profit from ordinary activities before Tax (7+8)	6,504.22	6,228.53	3,514.04	17,365.94	12,037.81	15,910.42
10	Tax expense	1,515.00	1,330.00	1,097.26	4,050.00	3,253.20	4,552.17
11	Net Profit from ordinary activities after Tax (9-10)	4,989.22	4,898.53	2,416.78	13,315.94	8,784.61	11,358.25
12	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.40	1,696.40	1,696.16	1,696.40	1,696.16	1,696.16
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	99,934.99
14	Earnings per share (EPS) (of Rs. 2/- each) (not annualised)						
	(1) Basic	5.88	5.78	2.85	15.70	10.36	13.40
	(2) Diluted	5.88	5.78	2.85	15.70	10.36	13.39
	See accompanying notes to the Financial Results						

NOTES

- The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on February 3, 2016.
- The statutory auditors have carried out limited review of the above financial results for the quarter ended on December 31, 2015.
- The other income includes Rs. 12.57 crores on account of profit / dividend on investments.
- The company is engaged in a single segment of activity viz. Pharmaceuticals.
- The previous quarter's/period's figures have been re-grouped/re-stated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai
Date : February 3, 2016

J.B.Mody
Chairman & Managing Director